L39 member EMV Capital invests in Vortex Biosciences

Level39 member EMV Capital has today announced the acquisition of a controlling stake in Vortex Biosciences, and a further investment package to accelerate the company’s development.

EMV Capital is an early-stage investor into B2B companies in the industrial high-tech, energy, smart city, transportation and healthcare sectors. Having been based at Level39 since 2015 – EMV Capital recently were awarded the EIS Newcomer of the Year award by the EIS Association.

Vortex Biosciences technology allows for extraction of a liquid biopsy of circulating tumour cells – providing highly-purified tumour cells, within 1 hour.

Robert Englert, CEO of Vortex Biosciences, commented “We will apply this new funding to achieve an expanded menu of downstream integration. Our vision at Vortex is to improve Cancer detection and therapy by providing the best CTC sample workflow from a standard tube of blood.”

EMV Capital MD Dr. Ilian Iliev said “As an IP-focused venture investor we understand the value that has been created by the Vortex team. We were impressed with the Vortex team’s vision on the central role they can play in the growing liquid biopsy market which is forecast to reach $8bn by 2023. Our support will help the company accelerate their growth in the North American and European markets, and expand the functionalities of the platform”


Related News